0 Bewertungen

ID

32387

Beschreibung

This ODM file contains the form to document all non-serious events that are temporally associated with the use of the study medication. Study ID: 101199 Clinical Study ID: 101199 Study Title: A randomized, double-blind, parallel group, placebo-controlled, single-attack evaluation of the efficacy and tolerability of TREXIMA™ (sumatriptan 85mg/naproxen sodium 500mg)* tablets vs placebo when administered during the mild pain phase of a migraine Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: sumatriptan Trade Name: Imitrex ,Imiject ,Imigran Study Indication: Migraine Disorders

Stichworte

  1. 29.10.18 29.10.18 -
  2. 30.10.18 30.10.18 -
Rechteinhaber

GlaxoSmithKline

Hochgeladen am

29. Oktober 2018

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY-NC 3.0

Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Itemgroup Kommentare für :

Item Kommentare für :


    Keine Kommentare

    Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

    Efficacy and Tolerability of TREXIMA™ (sumatriptan 85mg/naproxen sodium 500mg) ID 101199

    Non-Serious Adverse Event

    Administrative Data
    Beschreibung

    Administrative Data

    Alias
    UMLS CUI-1
    C1320722
    Subject Identifier
    Beschreibung

    Subject Identifier

    Datentyp

    text

    Alias
    UMLS CUI [1]
    C2348585
    Experience of a Non-Serious Adverse Event
    Beschreibung

    Experience of a Non-Serious Adverse Event

    Alias
    UMLS CUI-1
    C1518404
    Did the subject experience any non-serious adverse events during the study? If Yes, record details below.
    Beschreibung

    Any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e., lack of efficacy), abuse or misuse. Examples of an AE includes • Significant or unexpected worsening or exacerbation of the condition/ indication under study. • Exacerbation of a chronic or intermittent pre-existing condition including either an increase in frequency and/or intensity of the condition. • New condition(s) detected or diagnosed after investigational product administration even though it may have been present prior to the start of the study. • Signs, symptoms, or the clinical sequelae of a suspected interaction. • Signs, symptoms, or the clinical sequelae of a suspected overdose of either investigational product or a concomitant medication (overdose per se should not be reported as an AE/SAE). Examples of an AE does NOT include a/an • Medical or surgical procedure (e.g., endoscopy, appendectomy); the condition that leads to the procedure is an AE. • Situations where an untoward medical occurrence did not occur (social and/or convenience admission to a hospital). • Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present or detected at the start of the study that do not worsen. • The disease/disorder being studied, or expected progression, signs, or symptoms of the disease/disorder being studied, unless more severe than expected for the subject’s condition. For GSK clinical studies, AEs may include pre- or post-treatment events that occur as a result of protocol-mandated procedures (i.e., invasive procedures, modification of subject’s previous therapeutic regimen). See protocol for clarification. IF THIS EVENT MEETS THE DEFINITION OF SERIOUS, COMPLETE THE SERIOUS ADVERSE EVENT SECTION

    Datentyp

    text

    Alias
    UMLS CUI [1]
    C1518404
    Non-Serious Adverse Events Details
    Beschreibung

    Non-Serious Adverse Events Details

    Alias
    UMLS CUI-1
    C1518404
    Diagnosis Only (if known) Otherwise Sign/Symptom
    Beschreibung

    Enter only the diagnosis (if known); otherwise enter sign or symptom. If a diagnosis subsequently becomes available, then this should be entered and the sign or symptom crossed out, initialled and dated by the investigator.

    Datentyp

    text

    Alias
    UMLS CUI [1]
    C0011900
    Start Date
    Beschreibung

    Record the start date of the first occurrence of the AE.

    Datentyp

    date

    Alias
    UMLS CUI [1]
    C2697888
    Start Time
    Beschreibung

    Record the start time of the AE.

    Datentyp

    time

    Alias
    UMLS CUI [1]
    C2697888
    Outcome
    Beschreibung

    All AEs must be followed until the events are resolved, the condition stabilises, the events are otherwise explained, or the subject is lost to follow-up. Indicate if the event was ’Recovered/Resolved’ or ’Recovered/Resolved with sequelae’. If the AE is ongoing at the time the subject completes the study or becomes lost to follow-up, the outcome must be recorded as ’Not recovered/Not resolved’ or ’Recovering/Resolving’. Also enter ’Not recovered/Not resolved’ if the AE was ongoing at the time of death, but was not the cause of death.

    Datentyp

    text

    Alias
    UMLS CUI [1]
    C1705586
    End Date
    Beschreibung

    Record the end date. This is the date the AE Recovered/Resolved. If the event Recovered/Resolved with sequelae, enter the date the subject’s medical condition resolved or stabilised. Leave blank if the AE is ’Not recovered/Not resolved’ or ’Recovering/Resolving’.

    Datentyp

    date

    Alias
    UMLS CUI [1]
    C2697886
    Maximum Intensity
    Beschreibung

    Record the maximum intensity that occurred over the duration of the event. Amend the intensity if it increases. Mild = An event that is easily tolerated by the subject, causing minimal discomfort and not interfering with everyday activities. Moderate = An event that is sufficiently discomforting to interfere with normal everyday activities. Severe = An event that prevents normal everyday activities. Not applicable = those event(s) where intensity is meaningless or impossible to determine (i.e., blindness and coma).

    Datentyp

    text

    Alias
    UMLS CUI [1]
    C1710066
    Action Taken with Investigational Product(s) as a Result of the Non-Serious AE
    Beschreibung

    Investigational product(s) withdrawn = Dose reduced = Dose increased = Dose not changed = Dose interrupted = Not applicable = Administration of investigational product(s) was permanently discontinued. Dose is reduced for one or more investigational product(s). Dose increased for one or more investigational product(s). Investigational product(s) continues even though an adverse event has occurred. Administration of one or more investigational product(s) was stopped temporarily but then restarted. Subject was not receiving investigational product(s) when the event occurred (e.g., pre-or post-dosing).

    Datentyp

    text

    Alias
    UMLS CUI [1,1]
    C1704758
    UMLS CUI [1,2]
    C1518404
    Did the subject withdraw from study as a result of this AE?
    Beschreibung

    Indicate ’Yes’ if the event(s) were directly responsible for the subject’s withdrawal as indicated on the Study Conclusion page, otherwise indicate ’No’. If yes: Complete Study Conclusion page and tick Adverse event as reason for withdrawal.

    Datentyp

    text

    Is there a reasonable possibility that the AE may have been caused by the investigational product?
    Beschreibung

    It is a regulatory requirement for investigators to assess relationship to investigational product(s) based on information available. The assessment should be reviewed on receipt of any new information and amended if necessary. ’A reasonable possibility’ is meant to convey that there are facts/evidence or arguments to suggest a causal relationship. Facts/evidence or arguments that may support ’a reasonable possibility’ include, e.g., a temporal relationship, a pharmacologically-predicted event, or positive dechallenge or rechallenge. Confounding factors, such as concomitant medication, a concurrent illness, or relevant medical history, should also be considered.

    Datentyp

    text

    Alias
    UMLS CUI [1,1]
    C0304229
    UMLS CUI [1,2]
    C0085978
    UMLS CUI [1,3]
    C1518404

    Ähnliche Modelle

    Non-Serious Adverse Event

    Name
    Typ
    Description | Question | Decode (Coded Value)
    Datentyp
    Alias
    Item Group
    Administrative Data
    C1320722 (UMLS CUI-1)
    Subject Identifier
    Item
    Subject Identifier
    text
    C2348585 (UMLS CUI [1])
    Item Group
    Experience of a Non-Serious Adverse Event
    C1518404 (UMLS CUI-1)
    Item
    Did the subject experience any non-serious adverse events during the study? If Yes, record details below.
    text
    C1518404 (UMLS CUI [1])
    Code List
    Did the subject experience any non-serious adverse events during the study? If Yes, record details below.
    CL Item
    Yes (Y)
    CL Item
    No (N)
    Item Group
    Non-Serious Adverse Events Details
    C1518404 (UMLS CUI-1)
    Event
    Item
    Diagnosis Only (if known) Otherwise Sign/Symptom
    text
    C0011900 (UMLS CUI [1])
    Start Date of Adverse Event
    Item
    Start Date
    date
    C2697888 (UMLS CUI [1])
    Start Time of Adverse Event
    Item
    Start Time
    time
    C2697888 (UMLS CUI [1])
    Item
    Outcome
    text
    C1705586 (UMLS CUI [1])
    Code List
    Outcome
    CL Item
    Recovered/Resolved (1)
    (Comment:en)
    CL Item
    Recovering/Resolving (2)
    (Comment:en)
    CL Item
    Not recovered/Not resolved (3)
    (Comment:en)
    CL Item
    Recovered/Resolved with sequelae (4)
    (Comment:en)
    End Date of Adverse Event
    Item
    End Date
    date
    C2697886 (UMLS CUI [1])
    Item
    Maximum Intensity
    text
    C1710066 (UMLS CUI [1])
    Code List
    Maximum Intensity
    CL Item
    Mild (1)
    CL Item
    Moderate (2)
    CL Item
    Severe (3)
    CL Item
    Not applicable (X)
    Item
    Action Taken with Investigational Product(s) as a Result of the Non-Serious AE
    text
    C1704758 (UMLS CUI [1,1])
    C1518404 (UMLS CUI [1,2])
    Code List
    Action Taken with Investigational Product(s) as a Result of the Non-Serious AE
    CL Item
    Investigational product(s) withdrawn (1)
    CL Item
    Dose reduced (2)
    CL Item
    Dose increased (3)
    CL Item
    Dose not changed  (4)
    CL Item
    Dose interrupted (5)
    CL Item
    Not applicable (X)
    Item
    Did the subject withdraw from study as a result of this AE?
    text
    Code List
    Did the subject withdraw from study as a result of this AE?
    CL Item
    Yes (Y)
    CL Item
    No (N)
    Item
    Is there a reasonable possibility that the AE may have been caused by the investigational product?
    text
    C0304229 (UMLS CUI [1,1])
    C0085978 (UMLS CUI [1,2])
    C1518404 (UMLS CUI [1,3])
    Code List
    Is there a reasonable possibility that the AE may have been caused by the investigational product?
    CL Item
    Yes (Y)
    CL Item
    No (N)

    Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

    Zum Video